Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Other Operating Expenses (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Other Operating Expenses data on record, last reported at $1.9 million in Q3 2025.

  • For Q3 2025, Other Operating Expenses rose 62.58% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $10.9 million, up 50.76%, while the annual FY2024 figure was $6.8 million, 50.88% down from the prior year.
  • Other Operating Expenses reached $1.9 million in Q3 2025 per COEP's latest filing, down from $3.9 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $30.9 million in Q4 2022 and bottomed at -$5.0 million in Q3 2022.
  • Average Other Operating Expenses over 5 years is $3.9 million, with a median of $1.9 million recorded in 2023.
  • Peak YoY movement for Other Operating Expenses: crashed 5064.92% in 2022, then skyrocketed 4345.98% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $13.7 million in 2021, then soared by 125.45% to $30.9 million in 2022, then crashed by 93.79% to $1.9 million in 2023, then fell by 24.11% to $1.5 million in 2024, then increased by 29.06% to $1.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $1.9 million in Q3 2025, $3.9 million in Q2 2025, and $3.7 million in Q1 2025.